Bigfoot Biomedical

Milpitas, CA Healthcare Acquired

Bigfoot Biomedical is a medical device company headquartered in Milpitas, California that developed the Bigfoot Unity smart insulin management system. The system features FDA-cleared connected insulin pen caps that translate continuous glucose monitor data into insulin dosing recommendations. The company was founded in 2014 by Jeffrey Brewer (former JDRF CEO), Bryan Mazlish, and Lane Desborough (former Medtronic chief engineer). Bigfoot Unity works with FreeStyle Libre 2 sensors and all major brands of disposable insulin pens, approved for patients 12 years and older requiring multiple daily insulin injections. Abbott Laboratories completed acquisition of Bigfoot Biomedical on September 22, 2023.

Acquired

Bigfoot Biomedical has been acquired

Acquired by Abbott Laboratories September 22, 2023

This company is no longer available on our private secondary market.

Overview

Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.

Founded

2014

Employees

51–200

Total Funding

$146M

6 rounds

Funding

Total raised $146M across 6 rounds

Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.

Last updated 05-07-2026

Latest Round

Type

Series C Extension

Date

June 2020

Amount

$10M

Valuation

DateRoundAmount RaisedValuationLead Investors
June 2020 Series C Extension $10M
January 2020 Series C $45M
June 2018 Series B Extension $18M

Leadership

  • Jeffrey Brewer

    Cofounder, President & CEO

    LinkedIn
  • Bryan Mazlish

    Cofounder

  • Lane Desborough

    Cofounder, Chief Engineer

Competitors

Competitor list is illustrative and may be incomplete, stale, or erroneous.

  • Medtronic

    Offers InPen smart insulin pen system integrated with Guardian Connect continuous glucose monitoring for multiple daily injection therapy

  • Novo Nordisk

    Produces NovoPen 6 and NovoPen Echo Plus smart insulin pens; acquired minority stake in Bigfoot Biomedical in July 2023

  • Eli Lilly

    Developed Tempo Pen and Tempo Smart Button personalized diabetes management platform; compatible with Bigfoot capware

  • Sanofi

    Major insulin manufacturer with smart insulin pen offerings; Bigfoot caps compatible with Sanofi rapid- and long-acting pens

  • Roche

    Glucose monitoring and diabetes management company; partnered with Novo Nordisk on mySugr integration for smartpen data logging

Access live market data

Sign Up

Data collected with AI, which can make mistakes. Please double-check this information.